Klin Farmakol Farm. 2010;24(2):80-84

Utilization of inhalational corticosteroids in various types of bronchial obstruction

Vladimír Koblížek, Vratislav Sedlák
Plicní klinika FN a LF UK v Hradci Králové

This review article discusses the utilization of inhalational corticosteroids in treatment of the patients with bronchial obstruction. The

main indication of inhalational corticosteroids still remains mainly bronchial asthma. In people suffering from chronic obstructive pulmonary

disease, the clinical benefit of inhaled therapy is evident only for some specific phenotypes (in patients with recurrent acute

exacerbations, in patients with severe bronchial obstruction, in patients with a higher degree of reversibility of bronchial obstruction

and in individuals with the simultaneous chronic obstructive disease and asthma). Topic of many debates remains the use of inhalational

steroids in patients with bronchiectasis, cystic fibrosis and sarcoidosis. Utilization of inhalational steroids in the treatment of lower

respiratory tract is still a topical issue of many scientific papers. Therefore, we can only look forward to further information clarifying

our view on this issue.

Keywords: inhalational corticosteroids, chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis, bronchiectasis

Published: July 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Koblížek V, Sedlák V. Utilization of inhalational corticosteroids in various types of bronchial obstruction. Klin Farmakol Farm. 2010;24(2):80-84.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McGhen RM. Airway disease: Corticosteroids. In: Albert R, Spiro S, Jett J. Clinical Respiratory Medicine. Third edition. Mosby 2008: 483-489. Go to original source...
    2. Barnes P. How corticosteroids control inflammation. Br J Pharmacol 2006; 148: 245-254. Go to original source... Go to PubMed...
    3. Horvath G, Wanner A. Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. Eur Respir J 2006; 27: 172-187. Go to original source... Go to PubMed...
    4. Salajka F, Kašák V, Pohunek P, et al. Diagnostika, léčba a prevence průduškového astmatu v České republice. GINA 2008.
    5. Barnes P. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-191. Go to original source... Go to PubMed...
    6. Caverley P, Anderson J, Celli B, et al. Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. NEJM 2007; 8: 775-789. Go to original source... Go to PubMed...
    7. Tashkin D, Murray H, Skeans M, et al. Skin manifestations of inhaled corticosteroids in COPD patiens: results from Lung Health Study II. Chest 2004; 126: 1123-1133. Go to original source... Go to PubMed...
    8. Wedzicha J, Calverley P, Seemungal T, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionáte or tiotropium bromide. AJRCCM 2008; 177: 19-26. Go to original source... Go to PubMed...
    9. Singanayagam A, Chalmers JD, Hill AT. Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. QJM 2010; 103(6): 379-385. Go to original source... Go to PubMed...
    10. Crim C, Calverley P, Anderson J, et al. Pneumonia risk in COPD patiens receiving inhaled corticosteroids alone or in combination: TORCH study results. ERJ 2009 (doi: 10.1183/09031936.00193908). Go to original source... Go to PubMed...
    11. Souza-Machado C, Souza Machado A, Franco R, et al. Rapid reduction in hospitalisations after an intervention to manage severe asthma. Eur Respir J 2010; 35: 515-521. Go to original source... Go to PubMed...
    12. Derendorf H, Nave R, Drollman A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006; 28: 1042-1050. Go to original source... Go to PubMed...
    13. Aaron S, Vandemheen K, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. NEJM 2003; 348: 2618-2625. Go to original source... Go to PubMed...
    14. Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulised budesonide and oral prednisolone with placebo in treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. AJRCCM 2002; 165: 698-703. Go to original source...
    15. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81. Go to original source... Go to PubMed...
    16. Calverley P. The role of corticosteroids in chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005; 26: 235-245. Go to original source... Go to PubMed...
    17. Vestbo J, Pauwels R, Anderson J, et al. Early onset of effect salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005; 60: 301-304. Go to original source... Go to PubMed...
    18. Sin D, Lacy P, York E, Man S. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. AJRCCM 2004; 170: 760-765. Go to original source... Go to PubMed...
    19. Barnes N, Qiu Y, Pavord I, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. AJRCCM 2006: 736-743. Go to original source...
    20. Barnes P, Ito K, Adcock I. Corticosteroid resistence in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004; 363: 731-733. Go to original source... Go to PubMed...
    21. Ito K, Ito M, Elliot W, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. NEJM 2005; 352: 1967-1976. Go to original source... Go to PubMed...
    22. Rodrigo G. Castro-Rodriquez J, Plaza V. Safety and Efficacy of Combined Long-Acting ?-Agonists and Inhaled Corticosteroids vs. Long-Acting ?-Agonists Monotherapy for Stable COPD. CHEST 2009; 136: 1029-1038. Go to original source... Go to PubMed...
    23. Rennard S, Vestbo J. Many The Many, ,Small COPDs": COPD Should Be an Orphan Disease. Chest 2008; 134: 623-627. Go to original source... Go to PubMed...
    24. Vestbo J, Anderson W, Coxson H, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008; 31: 869-873. Go to original source... Go to PubMed...
    25. Weiner, et al. Inhaled budesonide therapy for patients with patients with stable COPD. Chest 1995; 108: 1568-1571. Go to original source... Go to PubMed...
    26. Nisar M, Earis J, Pearson M, et al. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 555-559. Go to original source... Go to PubMed...
    27. Mahler D, Wire P, Horstman D, et al. Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary Disease. AJRCCM 2002; 166: 1084-1091. Go to original source... Go to PubMed...
    28. Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. AJRCCM 2000; 162: 1773-1777. Go to original source... Go to PubMed...
    29. Ferreira I, Hazari M, Gutierrez C, et al. Exhaled nitric oxide and hydrogen peroxide in patiens with chronic obstructive pulmonary disease. AJRCCM 2001; 164: 1012-1015. Go to original source...
    30. Brightling C, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356: 1480-1485. Go to original source... Go to PubMed...
    31. Leigh R, Pizzichini M, Morris M, et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006; 27: 964-971. Go to original source... Go to PubMed...
    32. Dummer J, Epton M, Cowan J, et al. Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease Using Exhaled Nitric Oxide. AJRCCM 2009; 180: 846-852. Go to original source... Go to PubMed...
    33. Lehtimäki L, Kankaanranta H, Saarelainen S, et al. Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. ERJ 2010; 35: 72-78. Go to original source... Go to PubMed...
    34. Jones P, Willits L, Burge P, Calverley P. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbation. Eur Respir J 2003; 21: 68-73. Go to original source... Go to PubMed...
    35. De Wachter E, Vanbesien J, De Schutter I, et al. Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with intraconazole and inhaled budesonide. Eur J Pediatr 2003; 162: 488-489. Go to original source... Go to PubMed...
    36. De Wachter E, Malfroot A, De Schutter I, et al. Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochromeP450. J Cyst Fibros 2003; 2(2): 72-75. Go to original source... Go to PubMed...
    37. Minicucci L, Severi G, Cresta L, et al. Impact of inhaled corticosteroids on the risk of early Pseudomonas aeruginosa acquisition in cystic fibrosis. Acta Paediatr 2003; 92: 684-687. Go to original source... Go to PubMed...
    38. Dezateux C, Walters S, Balfour-Lynn I. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2000; 2: CD001915. Go to original source... Go to PubMed...
    39. Balfour-Lynn I, Welch K. Inhaled corctisteroids for cystic fibrosis. Cochrane Database Syst Rev 2009 1: CD001915. Go to original source... Go to PubMed...
    40. Balfour-Lynn I. Anti-inflammatory approaches to cystic fibrosis airways disease. Curr Opin Pulm Med 2007; 13: 522-528. Go to original source... Go to PubMed...
    41. Ross K, Chmiel J, Konstan M. The role of inhaled corticosteroids in the management of cystic fibrosis. Paediatr Drugs 2009; 11: 101-113. Go to original source... Go to PubMed...
    42. Ren C, Pasta D, Rasouliyan L, et al. Relationship between inhaled corticosteroid therapy aand rate of lung function decline in children with cystic fibrosis. J Pediatr 2008; 15: 746-751. Go to original source... Go to PubMed...
    43. De Boeck K, De Baets F, Malfroot A, et al. Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients? Eur J Pediatr 2007; 166: 23-28. Go to original source... Go to PubMed...
    44. Balfour-Lynn I, Lees B, Hall P, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. AJRCCM 2006; 173: 1356-1362. Go to original source... Go to PubMed...
    45. Ritz N, Ammann R, Casaulta Aebischer C, et al. Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis. Eur J Pediatr 2005; 164(9): 577-582. Go to original source... Go to PubMed...
    46. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database of Systematic Reviews 2009, Issue 1. Go to original source...
    47. King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? Drugs 2007; 67: 965-974. Go to original source... Go to PubMed...
    48. Tsang K, Bilton D.Clinical challenges in managing bronchiectasis. Respirology 2009; 14: 637-650. Go to original source... Go to PubMed...
    49. Guran T, Ersu R, Karadag B, et al. Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis. J Clin Pharm Ther 2008; 33: 603-611. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.